Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation

Zuoheng Fan, Prabir Chakravarty, Alan Alfieri, Tej K. Pandita, Bhadrasain Vikram, Chandan Guha

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Treatment failure after radiation therapy of prostate cancer (PC) could be a significant problem. Our objective is to design genetic radiosensitizing strategies for the treatment of PC. Cells from individuals with the genetic disorder ataxia telangiectasia (AT) are hypersensitive to ionizing radiation. Therefore, we examined whether attenuation of the AT gene product, AT mutated (ATM), in PC cells could result in an increased intrinsic radiosensitivity. A p53-mutant PC cell line, PC-3 was infected with adenoviral vectors, expressing antisense ATM RNA to various domains of the ATM gene. Immunoblot analyses of CellUlar extracts from antisense ATM-transfected PC-3 cells showed attenuated expression of the ATM protein within 2 days of viral infection. Compared with cells infected with an adeno-β-galactosidase vector, antisense ATM-transfected PC-3 cells showed aberrant control of S-phase cell-cycle checkpoints after exposure to ionizing radiation. Under these conditions, the intrinsic radiosensitivity of the PC-3 cells was enhanced. Consequently antisense ATM gene therapy could serve as a paradigm for strategies that target the cellular survival mechanisms of an irradiated tumor cell and may provide therapeutic benefit to patients undergoing radiation therapy for PC.

Original languageEnglish (US)
Pages (from-to)1307-1314
Number of pages8
JournalCancer Gene Therapy
Volume7
Issue number10
StatePublished - 2000

Fingerprint

Adenoviridae
Prostatic Neoplasms
Radiation
Genes
Ataxia Telangiectasia
Radiation Tolerance
Ionizing Radiation
Radiotherapy
S Phase Cell Cycle Checkpoints
Ataxia Telangiectasia Mutated Proteins
Galactosidases
Inborn Genetic Diseases
Virus Diseases
Treatment Failure
Genetic Therapy
RNA
Cell Line
Survival
Therapeutics

Keywords

  • Adenovirus
  • Antisense
  • ATM
  • Prostate cancer
  • Radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Fan, Z., Chakravarty, P., Alfieri, A., Pandita, T. K., Vikram, B., & Guha, C. (2000). Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation. Cancer Gene Therapy, 7(10), 1307-1314.

Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation. / Fan, Zuoheng; Chakravarty, Prabir; Alfieri, Alan; Pandita, Tej K.; Vikram, Bhadrasain; Guha, Chandan.

In: Cancer Gene Therapy, Vol. 7, No. 10, 2000, p. 1307-1314.

Research output: Contribution to journalArticle

Fan, Z, Chakravarty, P, Alfieri, A, Pandita, TK, Vikram, B & Guha, C 2000, 'Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation', Cancer Gene Therapy, vol. 7, no. 10, pp. 1307-1314.
Fan Z, Chakravarty P, Alfieri A, Pandita TK, Vikram B, Guha C. Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation. Cancer Gene Therapy. 2000;7(10):1307-1314.
Fan, Zuoheng ; Chakravarty, Prabir ; Alfieri, Alan ; Pandita, Tej K. ; Vikram, Bhadrasain ; Guha, Chandan. / Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation. In: Cancer Gene Therapy. 2000 ; Vol. 7, No. 10. pp. 1307-1314.
@article{c224533e96fe4739b78b8e4491e9f78a,
title = "Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation",
abstract = "Treatment failure after radiation therapy of prostate cancer (PC) could be a significant problem. Our objective is to design genetic radiosensitizing strategies for the treatment of PC. Cells from individuals with the genetic disorder ataxia telangiectasia (AT) are hypersensitive to ionizing radiation. Therefore, we examined whether attenuation of the AT gene product, AT mutated (ATM), in PC cells could result in an increased intrinsic radiosensitivity. A p53-mutant PC cell line, PC-3 was infected with adenoviral vectors, expressing antisense ATM RNA to various domains of the ATM gene. Immunoblot analyses of CellUlar extracts from antisense ATM-transfected PC-3 cells showed attenuated expression of the ATM protein within 2 days of viral infection. Compared with cells infected with an adeno-β-galactosidase vector, antisense ATM-transfected PC-3 cells showed aberrant control of S-phase cell-cycle checkpoints after exposure to ionizing radiation. Under these conditions, the intrinsic radiosensitivity of the PC-3 cells was enhanced. Consequently antisense ATM gene therapy could serve as a paradigm for strategies that target the cellular survival mechanisms of an irradiated tumor cell and may provide therapeutic benefit to patients undergoing radiation therapy for PC.",
keywords = "Adenovirus, Antisense, ATM, Prostate cancer, Radiation therapy",
author = "Zuoheng Fan and Prabir Chakravarty and Alan Alfieri and Pandita, {Tej K.} and Bhadrasain Vikram and Chandan Guha",
year = "2000",
language = "English (US)",
volume = "7",
pages = "1307--1314",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation

AU - Fan, Zuoheng

AU - Chakravarty, Prabir

AU - Alfieri, Alan

AU - Pandita, Tej K.

AU - Vikram, Bhadrasain

AU - Guha, Chandan

PY - 2000

Y1 - 2000

N2 - Treatment failure after radiation therapy of prostate cancer (PC) could be a significant problem. Our objective is to design genetic radiosensitizing strategies for the treatment of PC. Cells from individuals with the genetic disorder ataxia telangiectasia (AT) are hypersensitive to ionizing radiation. Therefore, we examined whether attenuation of the AT gene product, AT mutated (ATM), in PC cells could result in an increased intrinsic radiosensitivity. A p53-mutant PC cell line, PC-3 was infected with adenoviral vectors, expressing antisense ATM RNA to various domains of the ATM gene. Immunoblot analyses of CellUlar extracts from antisense ATM-transfected PC-3 cells showed attenuated expression of the ATM protein within 2 days of viral infection. Compared with cells infected with an adeno-β-galactosidase vector, antisense ATM-transfected PC-3 cells showed aberrant control of S-phase cell-cycle checkpoints after exposure to ionizing radiation. Under these conditions, the intrinsic radiosensitivity of the PC-3 cells was enhanced. Consequently antisense ATM gene therapy could serve as a paradigm for strategies that target the cellular survival mechanisms of an irradiated tumor cell and may provide therapeutic benefit to patients undergoing radiation therapy for PC.

AB - Treatment failure after radiation therapy of prostate cancer (PC) could be a significant problem. Our objective is to design genetic radiosensitizing strategies for the treatment of PC. Cells from individuals with the genetic disorder ataxia telangiectasia (AT) are hypersensitive to ionizing radiation. Therefore, we examined whether attenuation of the AT gene product, AT mutated (ATM), in PC cells could result in an increased intrinsic radiosensitivity. A p53-mutant PC cell line, PC-3 was infected with adenoviral vectors, expressing antisense ATM RNA to various domains of the ATM gene. Immunoblot analyses of CellUlar extracts from antisense ATM-transfected PC-3 cells showed attenuated expression of the ATM protein within 2 days of viral infection. Compared with cells infected with an adeno-β-galactosidase vector, antisense ATM-transfected PC-3 cells showed aberrant control of S-phase cell-cycle checkpoints after exposure to ionizing radiation. Under these conditions, the intrinsic radiosensitivity of the PC-3 cells was enhanced. Consequently antisense ATM gene therapy could serve as a paradigm for strategies that target the cellular survival mechanisms of an irradiated tumor cell and may provide therapeutic benefit to patients undergoing radiation therapy for PC.

KW - Adenovirus

KW - Antisense

KW - ATM

KW - Prostate cancer

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0033754117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033754117&partnerID=8YFLogxK

M3 - Article

C2 - 11059687

AN - SCOPUS:0033754117

VL - 7

SP - 1307

EP - 1314

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 10

ER -